A Word from the ESMO President
Have you read the latest ESMO President’s letter? You’ll find the second newsletter of 2018 here
Our open access, online journal, ESMO Open is now listed in Pubmed Central, only 10-months after launch. Learn more about the journal!
Read the Editor's choice articles
ESMO members are invited to attend the 2018 GA, 22 October in Munich, Germany, during the ESMO Congress. Join us and approve the new ESMO Bylaws.
ESMO’s flagship scientific journal, Annals of Oncology, publishes editorials, reviews, original articles and letters related to oncology
The ESMO-MCBS scale is a validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
ESMO President Josep Tabernero explains proposed changes to the ESMO Bylaws, and how these changes will give members a greater say in the running of the Society. The Bylaws will be voted at the 2018 General Assembly on 22 October during #ESMO18 in Munich (open to ESMO members only)
21 Aug 2018
A new scale for tumour DNA mutations which will simplify and standardise choices for targeted cancer treatment has been agreed by leading cancer...
20 Aug 2018
Targeted stakeholder consultation
20 Aug 2018
Don't miss the opportunity! Application deadline extended: 24 August 2018
17 Aug 2018
Results based on retrospective analysis of two large randomised trials
16 Aug 2018
Lenalidomide Accord is intended for the treatment of multiple myeloma
14 Aug 2018
Intended change concerned both medicines in combination for first-line treatment of advanced renal cell carcinoma
Oxford, United Kingdom
01 Sep
- 03 Sep
2018
Naples, Italy
02 Sep
- 07 Sep
2018
Paris, France
14 Sep
- 15 Sep
2018
Singapore
19 Sep
- 20 Sep
2018
Singapore
21 Sep
- 22 Sep
2018
Valencia, Spain
28 Sep
- 29 Sep
2018
